CAR T-Cell Therapy as a Second-Line Treatment for LBCL
Miguel-Angel Perales, MD, shares insight into the factors he considers when deciding if a patient should receive CAR T-cell therapy in the second line.
EP: 1.The Expanding Utility of CAR T-Cell Therapy in LBCL
EP: 2.Sequencing With CAR T-Cell Therapy for LBCL
Now Viewing
EP: 3.CAR T-Cell Therapy as a Second-Line Treatment for LBCL
EP: 4.Understanding Malignancy Risks With the Use of CAR T-cell Therapies
EP: 5.Real World Findings for Liso-Cel in LBCL From the Cell Therapy Consortium
EP: 6.Expert Perspective on Real-World Follow-Up Analyses of Liso-Cel in LBCL
EP: 7.Bridging Therapy With CAR T-Cell Therapy in LBCL
EP: 8.The Impact of Real-World Analyses in the Utilization of CAR T-Cell Therapy in LBCL
EP: 9.The Future of CAR T-Cell Therapy in LBCL
EP: 10.Back to the Bench: Exploring the Potential of CAR T-Cell Therapy in Oncology
Recent Videos
Related Content
